• About us
• Contact

Advertisement

Organisation › Details

RheinCell Therapeutics GmbH

RheinCell develops and manufactures GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies. Its production pipeline focuses on high immune compatibility and low rejection potential, with a spotlight on solutions for off-the-shelf, allogenic therapeutics. RheinCell provides exclusive access to clinically approved and consented cord blood cells, proprietary cell reprogramming protocols, state-of-the-art cleanroom and cell culture facilities, GMP-compliant manufacturing processes, and a first-class community of iPSC workflow experts who also develop GMP-compliant differentiation protocols in close cooperation with customers. *

 

	Start	2017-09-14 restructured
	End	2017-09-07 bankruptcy/renamed
	Group	Catalent (Group)
	Predecessor	RheinCell Therapeutics GmbH (OLD, AG DüDo HRB 74790)
	Industry	iPSC technology (induced pluripotent stem cell technology)
	Person	Weißer, Jürgen U. (RheinCell Therapeutics 201709– Managing Director)
	Person 2	Riesner, Detlev (Evotec Biosystems 199906 Scientific Advisory Board + Qiagen Co-Founder)
	Region	Langenfeld
	Country	Germany
	Street	98 Berghausener Str.
	City	40764 Langenfeld
	Tel	+49-2173-32820
		Address record changed: 2021-06-25
Basic data	Employees	n. a.
		* Document for »About Section«: Catalent. (6/24/21). "Press Release: Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies". Somerset, NJ.
		Record changed: 2023-12-30

Advertisement

More documents for Catalent (Group)

• [1] Catalent, Inc.. (4/6/22). "Press Release: Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe". Somers, NJ....
• [2] Catalent. (6/24/21). "Press Release: Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies". Somerset, NJ....
• [3] T-Knife GmbH. (9/21/20). "Press Release: T-Knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy". Berlin & Somerset, NJ....
• [4] Catalent, Inc.. (2/3/20). "Press Release: Catalent, Inc. Announces Pricing of Public Offering of Common Stock". Somers, NJ....
• [5] Aldevron LLC. (5/15/18). "Press Release: Aldevron Names Marc Wolff Chief Financial Officer"....
• [6] Valerius Biopharma AG. (5/14/18). "Press Release: Catalent Biologics and Valerius Biopharma to Collaborate on Manufacture of Specialty Biosimilars". Somerset, NJ & Basel....
• [7] CRISPR Therapeutics AG. (11/8/17). "Press Release: CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update". Zug & Cambridge, MA....
• [8] CRISPR Therapeutics AG. (6/6/17). "Press Release: CRISPR Therapeutics and MaSTherCell SA Sign Service Agreement for the Development and Manufacturing of Allogeneic Cell Therapies". Basel, Cambridge, MA & Gosselies....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.